Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620839 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
A Phase 1 study, sponsored by Pamela Munster.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02620839: Clinical Trial Phase 1 study, sponsored by Pamela Munster.
NCT02620839 is a Phase 1 study that was terminated before completion, run by Pamela Munster. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02620839, a Phase 1 study, was terminated before completion, sponsored by Pamela Munster.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This phase Ib trial studies the best dose and side effects of alpelisib and cisplatin in treating patients with human papillomavirus (HPV) positive solid tumor malignancies. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving alpelisib and cisplatin may work better in treating patients with solid tumor malignancies.
Primary Outcome
Measured using CTCAE v.4.03
Interventions
- DRUG Cisplatin
- DRUG Alpelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-12-01 |
| Est. Completion | 2019-01-28 |
| Phase | Phase 1 |
Why NCT02620839 stopped before completion
NCT02620839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Cisplatin is the first listed.
NCT02620839 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02620839 about?
NCT02620839 is a clinical study titled "Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies". This phase Ib trial studies the best dose and side effects of alpelisib and cisplatin in treating patients with human papillomavirus (HPV) positive solid tumor malignancies. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherap...
What is the current status of trial NCT02620839?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-12-01. Estimated completion is 2019-01-28.
What interventions are being tested in trial NCT02620839?
The interventions under investigation include: Cisplatin (DRUG), Alpelisib (DRUG).
Who is sponsoring clinical trial NCT02620839?
This trial is sponsored by Pamela Munster, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02620839's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI